You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
The need for thorough phase II studies in medicines development for Alzheimer’s disease
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, October 2015
|
| DOI | 10.1186/s13195-015-0153-y |
| Pubmed ID | |
| Authors |
Julian A. Gray, David Fleet, Bengt Winblad |
| Abstract |
An important factor in the universal failure in phase III trials in mild to moderate Alzheimer's disease in the past decade is the lack of phase II clinical data prior to entering phase III, with common reliance on biomarker results alone. Conduction of two learn-confirm cycles according to the Sheiner model would allow go/no-go decision making to include reliable clinical efficacy data prior to conducting phase III and would likely bring the rate of late stage failure more into line with that of other neurological indications. In studies in earlier disease stages, combined phase IIB/III adaptive approaches merit consideration in view of the long timelines of each study, though advantages and disadvantages of this approach versus the classical development pathway still need careful assessment. |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 8% |
| Unknown | 23 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 20% |
| Student > Ph. D. Student | 4 | 16% |
| Student > Bachelor | 3 | 12% |
| Student > Master | 3 | 12% |
| Professor | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 7 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Computer Science | 2 | 8% |
| Medicine and Dentistry | 2 | 8% |
| Chemistry | 2 | 8% |
| Other | 7 | 28% |
| Unknown | 8 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2015.
All research outputs
#2,137,556
of 22,831,537 outputs
Outputs from Alzheimer's Research & Therapy
#447
of 1,224 outputs
Outputs of similar age
#32,734
of 284,375 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#13
of 16 outputs
Altmetric has tracked 22,831,537 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,224 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.0. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,375 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.